Tactile Systems Technology Inc
NASDAQ:TCMD
Intrinsic Value
Tactile Systems Technology, Inc. is a medical technology company. [ Read More ]
The intrinsic value of one TCMD stock under the Base Case scenario is 22.48 USD. Compared to the current market price of 15.86 USD, Tactile Systems Technology Inc is Undervalued by 29%.
Valuation Backtest
Tactile Systems Technology Inc
Run backtest to discover the historical profit from buying and selling TCMD stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Growth Optimism for 2023, Challenges for 2024, and Profitability Outlook for 2025
2023-Q4 Earnings Call
The company achieved a 14% growth in lymphedema, surpassing the forecasted 13% CAGR for the same period. No new sales representatives were added last year, but current staff showed increased productivity, a success expected to extend into the second half of this year. Anticipated technological advancements should simplify healthcare provider referrals, potentially lifting prescription volumes by year's end. 2025 is viewed optimistically, with investments maturing into assets that should improve both top-line growth and operating margins.
Balance Sheet Decomposition
Tactile Systems Technology Inc
Current Assets | 145.3m |
Cash & Short-Term Investments | 75.2m |
Receivables | 43.2m |
Other Current Assets | 26.9m |
Non-Current Assets | 136.1m |
PP&E | 25.3m |
Intangibles | 77.8m |
Other Non-Current Assets | 33m |
Current Liabilities | 41.1m |
Accounts Payable | 6.7m |
Accrued Liabilities | 25.5m |
Other Current Liabilities | 8.9m |
Non-Current Liabilities | 46.7m |
Long-Term Debt | 26.2m |
Other Non-Current Liabilities | 20.6m |
Earnings Waterfall
Tactile Systems Technology Inc
Revenue
|
274.4m
USD
|
Cost of Revenue
|
-137.4m
USD
|
Gross Profit
|
137.1m
USD
|
Operating Expenses
|
-119m
USD
|
Operating Income
|
18m
USD
|
Other Expenses
|
10.5m
USD
|
Net Income
|
28.5m
USD
|
Free Cash Flow Analysis
Tactile Systems Technology Inc
What is Free Cash Flow?
TCMD Profitability Score
Profitability Due Diligence
Tactile Systems Technology Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Tactile Systems Technology Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
TCMD Solvency Score
Solvency Due Diligence
Tactile Systems Technology Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Score
Tactile Systems Technology Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TCMD Price Targets Summary
Tactile Systems Technology Inc
According to Wall Street analysts, the average 1-year price target for TCMD is 21.08 USD with a low forecast of 17.17 USD and a high forecast of 26.25 USD.
Ownership
TCMD Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
TCMD Price
Tactile Systems Technology Inc
Average Annual Return | -25.25% |
Standard Deviation of Annual Returns | 36.56% |
Max Drawdown | -91% |
Market Capitalization | 374.3m USD |
Shares Outstanding | 23 600 600 |
Percentage of Shares Shorted | 6.05% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Tactile Systems Technology, Inc. is a medical technology company. The company is headquartered in Minneapolis, Minnesota and currently employs 988 full-time employees. The company went IPO on 2016-07-28. Its therapeutic focus is vascular disease, for treating lymphedema and chronic venous insufficiency. The company is a manufacturer and distributor of the Flexitouch and Entre systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition. Its at-home Flexitouch system provides automated, at-home lymphatic drainage therapy. Its Flexitouch Plus system is an automated, programmable, pneumatic compression device (APCD), designed for the treatment of lymphedema in the home setting. Its Entre system is a pneumatic compression device used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company possesses a platform to deliver at-home healthcare solutions directly to patients throughout the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one TCMD stock under the Base Case scenario is 22.48 USD.
Compared to the current market price of 15.86 USD, Tactile Systems Technology Inc is Undervalued by 29%.